Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August
No Summer Slowdown Yet For Venture Capital Deals
Executive Summary
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
You may also be interested in...
Hong Kong's First 2022 Biotech IPO Debuts
One IPO on the Hong Kong Stock Exchange and seven venture capital or private equity deals raised a combined $329m in China in February.
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.